Patent · US Active

CRISPR/Cas9 vector combination and application thereof in gene knockout

US11180763B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

Nanjing Genefriend-Biotech Inc. · CN

Inventors

Yifan Dai · Cleveland Heights, US
Haiyuan Yang · 安丰镇, CN
Ying Wang · South Setauket, US

Key dates

Filing date	Mar 14, 2019
Grant date	Nov 23, 2021
Priority date	—
Expiry date	Mar 14, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y204/01087
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Provided is an SgRNA combination, comprising an SgRNA specifically targeting the GGTA1 gene, an SgRNA specifically targeting the CMAH gene and an SgRNA specifically targeting the β4GalNT2 gene. Also provided is a CRISPR/Cas9 vector combination, comprising a GGTA1-CRISPR/Cas9 vector, a CMAH-CRISPR/Cas9 vector and a β4GalNT2-CRISPR/Cas9 vector. Also provided is an applicaton of the CRISPR/Cas9 vector combination in knocking out the GGTA1 gene, the CMAH gene and the β4GalNT2 gene. The knockout rates of the three genes with the specifically targeted SgRNA sequences are respectively 56%, 63%, and 41%. A three genes knockoutpig can be obtained, wherein the three genes related to immune rejectionare knocked out, and heart valves of said pig can be acquired.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.